Biocept Q3 Revenues Drop 31 Percent as Test Volume Shrinks

Nov 13, 2018

|

This story has been updated to include comments from Biocept's earnings call with analysts.

NEW YORK (GenomeWeb) – Biocept reported after the close of the market Tuesday that its third quarter 2018 revenues plunged 31 percent year over year as total test volumes shrank 28 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Biocept Q3 Revenues Drop 31 Percent as Test Volume Shrinks

To read the full story....

Breaking News

Quanterix Q4 Revenues Up 64 Percent

Oppenheimer Initiates Coverage of MDxHealth at Outperform

RenalytixAI Reports Q2 2021 Revenues of $400K

Guardant360 CDx Receives CE Mark for Tumor Mutational Profiling and Tagrisso CDx Use

Aegea, Biocept Ink Supply Agreement for Coronavirus MDx Test

Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service

What's Popular?

Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience for up to $695M

Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service

William Blair Initiates Coverage of Point-of-Care MDx Firm Lucira Health With Outperform Rating

OraSure Technologies Q4 Revenues Rise 27 Percent, Beat Analysts' Estimate

Hologic Acquires European MDx Firm Diagenode for Approximately $159M

Sponsorships